Abstract
Dyslipidemia, and especially atherogenic dyslipidemia, a combination of small low-density lipoproteins cholesterol (LDL-C), decreased high-density lipoprotein cholesterol (HDL-C) and increased triglyceride (TG) concentrations, represents a major cardiovascular (CV) risk factor. Nuclear receptor peroxisome proliferator-activated receptors (PPARs) are involved in the regulation of lipid metabolism; PPAR ligands are used to treat dyslipidemias.
Fibrates have a major impact on TG metabolism as well as on modulating LDL size and subclasses. Fibrates target atherogenic dyslipidemia by increasing plasma HDL-C concentrations and decreasing small dense LDL (sdLDL) particles and TGs, thus contributing to dyslipidemia management, particularly in patients with diabetes (DM) or the metabolic syndrome (MetS). Furthermore, fibrates exert beneficial effects on adipokines, inflammation and oxidative stress as well as neuroprotective properties. However, further studies are needed to define the role of fibrates in the prevention of CV events. We review the effects of fibrates on atherogenic dyslipidemia and CV risk reduction.
Keywords: Fibrates, dyslipidemia, cardiovascular risk, diabetes.
Current Pharmaceutical Design
Title:The Role of Fibrate Treatment in Dyslipidemia: An Overview
Volume: 19 Issue: 17
Author(s): Niki Katsiki, Dragana Nikolic, Giuseppe Montalto, Maciej Banach, Dimitri P. Mikhailidis and Manfredi Rizzo
Affiliation:
Keywords: Fibrates, dyslipidemia, cardiovascular risk, diabetes.
Abstract: Dyslipidemia, and especially atherogenic dyslipidemia, a combination of small low-density lipoproteins cholesterol (LDL-C), decreased high-density lipoprotein cholesterol (HDL-C) and increased triglyceride (TG) concentrations, represents a major cardiovascular (CV) risk factor. Nuclear receptor peroxisome proliferator-activated receptors (PPARs) are involved in the regulation of lipid metabolism; PPAR ligands are used to treat dyslipidemias.
Fibrates have a major impact on TG metabolism as well as on modulating LDL size and subclasses. Fibrates target atherogenic dyslipidemia by increasing plasma HDL-C concentrations and decreasing small dense LDL (sdLDL) particles and TGs, thus contributing to dyslipidemia management, particularly in patients with diabetes (DM) or the metabolic syndrome (MetS). Furthermore, fibrates exert beneficial effects on adipokines, inflammation and oxidative stress as well as neuroprotective properties. However, further studies are needed to define the role of fibrates in the prevention of CV events. We review the effects of fibrates on atherogenic dyslipidemia and CV risk reduction.
Export Options
About this article
Cite this article as:
Katsiki Niki, Nikolic Dragana, Montalto Giuseppe, Banach Maciej, Mikhailidis Dimitri P. and Rizzo Manfredi, The Role of Fibrate Treatment in Dyslipidemia: An Overview, Current Pharmaceutical Design 2013; 19 (17) . https://dx.doi.org/10.2174/1381612811319170020
DOI https://dx.doi.org/10.2174/1381612811319170020 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Approaches in the Treatment of Atrial Fibrillation
Current Medicinal Chemistry The Role of Integrin-Mediated Cell Adhesion in Atherosclerosis: Pathophysiology and Clinical Opportunities
Current Pharmaceutical Design Potential Role of TRAIL in the Management of Autoimmune Diabetes Mellitus
Current Pharmaceutical Design Combinations of Plant Polyphenols & Anti-Cancer Molecules: A Novel Treatment Strategy for Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Alteration of the Beta-Adrenergic Signaling Pathway in Human Heart Failure
Current Pharmaceutical Biotechnology The Multi-modality Cardiac Imaging Approach to Cardiac Sarcoidosis
Current Medical Imaging Low Molecular Weight Heparins and Glomerular Filtration Rate: A Report to be Considered
Current Vascular Pharmacology Effects of Statins on Transplant Graft Arterial Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Targeting Na/K-ATPase Signaling: A New Approach to Control Oxidative Stress
Current Pharmaceutical Design Enterovirus D-68 Molecular Virology, Epidemiology, and Treatment: an Update and Way Forward
Infectious Disorders - Drug Targets Cell Penetrating Peptide Delivery of Splice Directing Oligonucleotides as a Treatment for Duchenne Muscular Dystrophy
Current Pharmaceutical Design Contextualizing Genetics for Regional Heart Failure Care
Current Cardiology Reviews Targeting the EGFR-family for Therapy: Biological Challenges and Clinical Perspective
Current Pharmaceutical Design The CD4C/HIVNef Transgenic Model of AIDS
Current HIV Research Pharmacological Regulators of Intracellular Calcium Release Channels
Current Pharmaceutical Design Exploring the Role of Gene Therapy for Neurological Disorders
Current Gene Therapy Proteomics to Identify Novel Biomarkers and Therapeutic Targets in Cardiovascular Disease
Letters in Drug Design & Discovery Insight γ-Secretase: Structure, Function, and Role in Alzheimer’s Disease
Current Drug Targets Measurement of Physical Changes in the Myocardium for Development of Novel Methods for Diagnosing Ischemia
Current Cardiology Reviews Endothelial Cell Regulation of Cardiac Metabolism Following Diabetes
Cardiovascular & Hematological Disorders-Drug Targets